These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 23164477)

  • 1. Safety and efficacy of the cobalt chromium PRO-Kinetik coronary stent system: results of the MULTIBENE study.
    Vermeersch P; Appelman Y; Horstkotte D; Richardt G; Boland J; Lalmand J; Coussement P; Castadot M; Janssens L; Agostoni P; Buysschaert I; Suttorp MJ
    Cardiovasc Revasc Med; 2012; 13(6):316-20. PubMed ID: 23164477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy and safety of PRO-kinetic metal alloy stent in hospitalized patients with acute ST-elevation myocardial infarction (The PROMETHEUS Study).
    Lim SY; Park HW; Chung WY; Kim SY; Kim KS; Bae JW; Youn TJ;
    J Invasive Cardiol; 2012 Jun; 24(6):270-3. PubMed ID: 22684380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective, multi-center evaluation of a silicon carbide coated cobalt chromium bare metal stent for percutaneous coronary interventions: two-year results of the ENERGY Registry.
    Erbel R; Eggebrecht H; Roguin A; Schroeder E; Philipp S; Heitzer T; Schwacke H; Ayzenberg O; Serra A; Delarche N; Luchner A; Slagboom T;
    Cardiovasc Revasc Med; 2014; 15(8):381-7. PubMed ID: 25456414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
    Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and angiographic experience with a third-generation drug-eluting Orsiro stent in the treatment of single de novo coronary artery lesions (BIOFLOW-I): a prospective, first-in-man study.
    Hamon M; Niculescu R; Deleanu D; Dorobantu M; Weissman NJ; Waksman R
    EuroIntervention; 2013 Jan; 8(9):1006-11. PubMed ID: 23339805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective multicenter parallel-controlled trial of TIVOLI biodegradable-polymer-based sirolimus-eluting stent compared to ENDEAVOR zotarolimus-eluting stent for the treatment of coronary artery disease: 8-month angiographic and 2-year clinical follow-up results.
    Xu B; Dou KF; Han YL; Lü SZ; Yang YJ; Huo Y; Wang LF; Chen YD; Wang HC; Li WM; Chen JY; Wang L; Wang Y; Ge JB; Li W; Gao RL
    Chin Med J (Engl); 2011 Mar; 124(6):811-6. PubMed ID: 21518585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical safety and efficacy of a novel thin-strut cobalt-chromium coronary stent system: results of the real world Coroflex Blue Registry.
    Bocksch W; Pomar F; Dziarmaga M; Tresukosol D; Ismail O; Janek B; Carlsson J; Simon JP;
    Catheter Cardiovasc Interv; 2010 Jan; 75(1):78-85. PubMed ID: 19739262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcome of percutaneous treatment of in-stent restenosis with drug-eluting stents: results from the first phase of the prospective multicentre German DES.DE registry.
    Abdel-Wahab M; Nienaber CA; Mostafa AE; Sabin G; Tebbe U; Hochadel M; Senges J; Akin I; Kuck KH; Hamm C; Richardt G;
    EuroIntervention; 2011 Jun; 7(2):201-8. PubMed ID: 21646062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical investigation into the observation that silicon carbide coating on cobalt chromium stents leads to early differentiating functional endothelial layer, increased safety and DES-like recurrent stenosis rates: results of the PRO-Heal Registry (PRO-Kinetic enhancing rapid in-stent endothelialisation).
    Dahm JB; Willems T; Wolpers HG; Nordbeck H; Becker J; Ruppert J
    EuroIntervention; 2009 Jan; 4(4):502-8. PubMed ID: 19284073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study.
    Krucoff MW; Kereiakes DJ; Petersen JL; Mehran R; Hasselblad V; Lansky AJ; Fitzgerald PJ; Garg J; Turco MA; Simonton CA; Verheye S; Dubois CL; Gammon R; Batchelor WB; O'Shaughnessy CD; Hermiller JB; Schofer J; Buchbinder M; Wijns W;
    J Am Coll Cardiol; 2008 Apr; 51(16):1543-52. PubMed ID: 18420096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sirolimus-eluting cobalt-chromium stents: two-year clinical results from first-in-man study on the Firebird 2 stent.
    Xu B; Zhang Q; Yang YJ; Qiao SB; Zhang RY; Zhang JS; Hu J; Qin XW; Hong T; Li JP; Chen JL; Huo Y; Gao RL; Shen WF
    Chin Med J (Engl); 2008 Mar; 121(6):492-7. PubMed ID: 18364131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term clinical outcome of thin-strut cobalt-chromium stents in the drug-eluting stent era: results of the COBALT (comparison of bare-metal stents in all-comers' lesion treatment) registry.
    Abdel-Wahab M; Toelg R; Kassner G; Klatt L; Sherif MA; Geist V; Richardt G
    J Interv Cardiol; 2011 Dec; 24(6):496-504. PubMed ID: 21981403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First report of a novel abluminal groove filled biodegradable polymer rapamycin-eluting stent in de novo coronary artery disease: results of the first in man FIREHAWK trial.
    Qian J; Xu B; Lansky AJ; Yang YJ; Qiao SB; Wu YJ; Chen J; Hu FH; Yang WX; Mintz GS; Leon MB; Gao RL
    Chin Med J (Engl); 2012 Mar; 125(6):970-6. PubMed ID: 22613516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective registry evaluating safety and efficacy of cobalt-chromium stent implantation in patients with de novo coronary lesions.
    Buszman P; Trznadel S; Zurakowski A; Milewski K; Kinasz L; Król M; Kondys M
    Kardiol Pol; 2007 Sep; 65(9):1041-6; discussion 1047-8. PubMed ID: 17975751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Firebird and cypher sirolimus-eluting stents and bare metal stents in treatment of very long coronary lesions.
    Fan L; Chen LL; Lin CG; Peng YF; Zheng XC; Luo YK; Zhang FL; Chen JH; Yan XP; Huang ZR
    Chin Med J (Engl); 2008 Aug; 121(16):1518-23. PubMed ID: 18982862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Everolimus-eluting stents compared with paclitaxel-eluting stents for treatment of coronary in-stent restenoses.
    Markovic S; Paliskyte R; Rottbauer W; Wöhrle J
    Cardiovasc Revasc Med; 2012; 13(6):307-10. PubMed ID: 23164475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biodegradable polymer-based, argatroban-eluting, cobalt-chromium stent (JF-04) for treatment of native coronary lesions: final results of the first-in-man study and lessons learned.
    Morino Y; Tobaru T; Yasuda S; Kataoka K; Tanabe K; Hirohata A; Kozuma K; Kimura T
    EuroIntervention; 2016 Nov; 12(10):1271-1278. PubMed ID: 27866136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow-up of drug-eluting stents when inserted for on- and off-label indications.
    Qasim A; Cosgrave J; Latib A; Colombo A
    Am J Cardiol; 2007 Dec; 100(11):1619-24. PubMed ID: 18036358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-year follow-up of the Genous™ endothelial progenitor cell capturing stent versus the Taxus Liberté stent in patients with de novo coronary artery lesions with a high-risk of restenosis: a randomized, single-center, pilot study.
    Beijk MA; Klomp M; van Geloven N; Koch KT; Henriques JP; Baan J; Vis MM; Tijssen JG; Piek JJ; de Winter RJ
    Catheter Cardiovasc Interv; 2011 Aug; 78(2):189-95. PubMed ID: 21542109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized comparison of everolimus-eluting stent versus sirolimus-eluting stent implantation for de novo coronary artery disease in patients with diabetes mellitus (ESSENCE-DIABETES): results from the ESSENCE-DIABETES trial.
    Kim WJ; Lee SW; Park SW; Kim YH; Yun SC; Lee JY; Park DW; Kang SJ; Lee CW; Lee JH; Choi SW; Seong IW; Lee BK; Lee NH; Cho YH; Shin WY; Lee SJ; Lee SW; Hyon MS; Bang DW; Park WJ; Kim HS; Chae JK; Lee K; Park HK; Park CB; Lee SG; Kim MK; Park KH; Choi YJ; Cheong SS; Yang TH; Jang JS; Her SH; Park SJ;
    Circulation; 2011 Aug; 124(8):886-92. PubMed ID: 21810659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.